www.luntacunt.fora.pl
Luntacunt project
www.luntacunt.fora.pl Forum Index
->
Assignments
Post a reply
Username
Subject
Message body
Emoticons
View more Emoticons
Font colour:
Default
Dark Red
Red
Orange
Brown
Yellow
Green
Olive
Cyan
Blue
Dark Blue
Indigo
Violet
White
Black
Font size:
Tiny
Small
Normal
Large
Huge
Close Tags
Options
HTML is
OFF
BBCode
is
ON
Smilies are
ON
Disable BBCode in this post
Disable Smilies in this post
Confirmation code: *
All times are GMT + 2 Hours
Select a forum
Team
----------------
Rules
Announcements
Assignments
Forge
Legal / publishing
Tips & Tricks
Pub
Design
----------------
Genre
Technologie
Implementacja
----------------
Schedule
Snapshots
Topic review
Author
Message
cheapbag214s
Posted: Wed 14:23, 27 Nov 2013
Post subject: April 10
U.S. grants $3.5 million to develop multiple vaccine device
BLUE BELL, Pa., April 10 () -- A $3.5 million grant is being given a U.S. public/private partnership for advancing development of a new device to simultaneously deliver multiple vaccines.Receiving the grant from the National Institute of Allergy and Infectious Diseases is Inovio Pharmaceuticals Inc., which is collaborating with the chief scientist at the U.S. Army Medical Research Institute of Infectious Diseases.The device to be developed would administer multiple synthetic vaccines -- via skin surface electroporation,[url=http://www.hotyoupro.com]The north face jackets sale[/url], or electrical introduction – to U.S. troops to protect against diseases and to civilian populations to protect against pandemic threats."This new device would provide a means to rapidly and painlessly deliver multiple vaccines simultaneously to large groups of people," said Dr. J. Joseph Kim, Inovio's president and chief executive officer. "This collaboration builds on Inovio's strong relationship with Dr. Connie Schmaljohn and her team at USAMRIID in which Inovio is bringing medical innovation to several biodefense efforts."Moreover,[url=http://www.hotyoupro.com]The north face outlet store[/url], the advancements from this project will enable rapid and efficient delivery of Inovio's SynCon®vaccines for universal flu, HIV, and other infectious diseases on a mass scale."Inovio said in an earlier joint effort with USAMRIID, an optimized DNA vaccine for the Lassa virus delivered by surface electroporation demonstrated complete protection against the virus in animal subjects but improvements are still needed to make the electroporation technology more suitable for multiple vaccine administrations and mass vaccinations.
fora.pl
- załóż własne forum dyskusyjne za darmo
Powered by
phpBB
© 2001-2003 phpBB Group
Theme created by
Vjacheslav Trushkin
Regulamin